

INCYTE GENOMICS INC  
Form POS AM  
October 17, 2002

As filed with the Securities and Exchange Commission on October 17, 2002.

Registration No. 333-36318

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## Post-Effective Amendment No. 1 to Form S-3

REGISTRATION STATEMENT  
Under  
THE SECURITIES ACT OF 1933

### INCYTE GENOMICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

94-3136539

---

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

3160 Porter Drive  
Palo Alto, California 94304  
(650) 855-0555

---

(Address, including zip code, and telephone number, including area code,  
of registrant's principal executive offices)

PAUL A. FRIEDMAN  
Chief Executive Officer  
Incyte Genomics, Inc.  
3160 Porter Drive  
Palo Alto, California 94304  
(415) 855-0555

Copy to:  
STANTON D. WONG, ESQ.  
Pillsbury Winthrop LLP  
P.O. Box 7880  
San Francisco, CA 94120-7880  
(415) 983-1000

---

(Name, address, including zip code, and telephone  
number, including area code, of agent for service)

---

**DEREGISTRATION OF UNSOLD SECURITIES**

On May 4, 2000, Incyte Genomics, Inc. (the Company) filed its Registration Statement on Form S-3 (File No. 333-36318) (the Registration Statement) covering \$200,000,000 principal amount of 5.5% Convertible Subordinated Notes due 2007 (the Notes) and the 1,483,250 shares of the Company's common stock, \$0.001 par value (Common Stock), issuable upon conversion of such Notes (as subsequently adjusted for the September 2000 two-for-one stock split) to be sold by certain selling securityholders of the Company. On August 2, 2000, the Securities and Exchange Commission (the Commission) declared the Registration Statement effective.

Pursuant to Rule 477 promulgated under the Securities Act of 1933 and the Company's undertaking in Item 17 of Part II of this Registration Statement, the Company respectfully requests that the Commission withdraw the Company's Registration Statement on Form S-3, including all amendments and exhibits thereto, with respect to the unsold portion of securities registered hereon. The Registration Statement was filed in order to register the Notes issued to purchasers in a private placement in February 2000 and the shares of Common Stock into which the Notes are convertible.

The Company is requesting the withdrawal of the Registration Statement because, pursuant to the terms of the Registration Rights Agreement between the Company and the initial purchasers of the Notes, the Company's obligations to maintain the effectiveness of the Registration Statement under the Registration Rights Agreement expired in February 2002.

Accordingly, the Company hereby de-registers the Notes, and shares of its Common Stock into which the Notes are convertible, registered pursuant to the Registration Statement that remain unsold thereunder.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, on the 17th day of October 2002.

**INCYTE GENOMICS, INC.**

By:           /s/ PAUL A.  
          FRIEDMAN          

Paul A. Friedman  
*Chief Executive  
Officer  
(Principal Executive  
Officer)*

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the date indicated:

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<p><u>          /s/ PAUL A. FRIEDMAN          </u>  Paul A. Friedman</p>	<p>Chief Executive Officer (Principal Executive Officer) and Director</p>	<p>October 17, 2002</p>
<p><u>          /s/ JOHN M. VUKO          </u>  John M. Vuko</p>	<p>Chief Financial Officer (Principal Financial Officer)</p>	<p>October 17, 2002</p>
<p><u>          /s/ TIMOTHY G. HENN          </u>  Timothy G. Henn</p>	<p>Controller (Principal Accounting Officer)</p>	<p>October 17, 2002</p>
<p><u>          * /s/ ROY A. WHITFIELD          </u>  Roy A. Whitfield</p>	<p>Chairman of the Board</p>	<p>October 17, 2002</p>
<p><u>          /s/ ROBERT B. STEIN          </u>  Robert B. Stein</p>	<p>President, Chief Scientific Officer and Director</p>	<p>October 17, 2002</p>

Edgar Filing: INCYTE GENOMICS INC - Form POS AM

---

<u>Signature</u>	<u>Title</u>	<u>Date</u>
_____ Barry M. Ariko	Director	_____, 2002
_____ Julian C. Baker	Director	_____, 2002
_____ Paul A. Brooke	Director	_____, 2002
* /s/ JEFFREY J. COLLINSON _____ Jeffrey J. Collinson	Director	October 17, 2002
* /s/ FREDERICK B. CRAVES _____ Frederick B. Craves	Director	October 17, 2002
_____ Richard U. De Schutter	Director	_____, 2002
* /s/ JON S. SAXE _____ Jon S. Saxe	Director	October 17, 2002
* By: _____ Lee Bendekgey As Attorney-In-Fact		